Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Hypopharyngeal cancer
Results 1-25 of 164 for your search:
Start Over
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG-1216, NCI-2013-00500, NCT01810913
Acupuncture in Treating Dry Mouth Caused by Radiation Therapy in Patients with Head and Neck Cancer
Status: Active
Phase: Phase III
Type: Supportive care
Age: Not specified
Trial IDs: MDA-04-01, NCI-2011-02073, WFU 97115, CDR0000674208, WF-97115, NCT01141231
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients with Head and Neck Cancer Undergoing Radiation Therapy
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: ENT0042, NCI-2015-00176, 32439, NCT02369835
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D4193C00002, NCI-2015-01842, NCT02369874
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D419LC00001, NCI-2015-02221, NCT02551159
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 603EUSA03, NCI-2010-01741, NCT00901732
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients with Cancer Receiving Anti-Angiogenesis Therapy
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: VARIMG0002, NCI-2013-00535, NCT01806675
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADXS001-04, NCI-2015-01212, NCT02291055
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204 / ECHO-204, NCI-2015-00040, INCB 24360-204, NCT02327078
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5660C00004, NCI-2015-01342, NCT02499328
A Study to Investigate the Safety and Efficacy of Nivolumab and Nivolumab Plus Ipilimumab in Virus-associated Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9383, NCI-2015-01310, MK-3475, NCT02538510
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IPH2201-203, NCI-2016-00212, NCT02643550
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7080-A001-111, NCI-2016-00529, NCT02501096
Dynasplint Trismus System or Tongue Depressors in Reducing Trismus in Patients With Previously Treated Head and Neck Cancer
Status: Temporarily closed
Phase: Phase II
Type: Supportive care
Age: 20 and over
Trial IDs: UAB0780, NCI-2011-03029, HNO 0602, NCT00507208
Start Over